{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T16:56:07Z","timestamp":1792169767598,"version":"4.4.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013238","name":"Mahidol University Faculty of Medicine Siriraj Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013238","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010558","name":"Beiersdorf AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010558","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"NIAMS","doi-asserted-by":"publisher","award":["R01-AR082675"],"award-info":[{"award-number":["R01-AR082675"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014989","name":"Chan Zuckerberg Initiative","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014989","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jidinnovations.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JID Innovations"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.xjidi.2026.100508","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:40:03Z","timestamp":1786034403000},"page":"100508","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Complete remission after rituximab therapy of pemphigus: Real-world evidence on dosing regimens and retreatment strategies"],"prefix":"10.1016","volume":"6","author":[{"given":"Chuda","family":"Rujitharanawong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasima","family":"Tongsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimee S.","family":"Payne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xjidi.2026.100508_bib1","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.jaad.2025.05.1374","article-title":"Efficacy, safety, and B-cell depletion capacity of 3 rituximab dosing regimens in the treatment of moderate-to-severe pemphigus vulgaris and pemphigus foliaceus: a 52-week clinical trial","volume":"93","author":"Cao","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2026.100508_bib2","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.93222","article-title":"Robust memory responses against influenza vaccination in pemphigus patients previously treated with rituximab","volume":"2","author":"Cho","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.xjidi.2026.100508_bib3","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1681\/ASN.2015050523","article-title":"B cell reconstitution after rituximab treatment in idiopathic nephrotic syndrome","volume":"27","author":"Colucci","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.xjidi.2026.100508_bib4","series-title":"Rituxan (rituximab) injection, for intravenous use","year":"2019"},{"key":"10.1016\/j.xjidi.2026.100508_bib5","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1038\/jid.2014.291","article-title":"Persistence of anti-desmoglein 3 IgG(+) B-cell clones in pemphigus patients over years","volume":"135","author":"Hammers","year":"2015","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.xjidi.2026.100508_bib6","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial","volume":"389","author":"Joly","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.xjidi.2026.100508_bib7","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1111\/ajt.12220","article-title":"A single dose of rituximab does not deplete B cells in secondary lymphoid organs but alters phenotype and function","volume":"13","author":"Kamburova","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.xjidi.2026.100508_bib8","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1001\/jamadermatol.2019.3236","article-title":"Factors associated with complete remission after rituximab therapy for pemphigus","volume":"155","author":"Kushner","year":"2019","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.xjidi.2026.100508_bib9","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/art.21617","article-title":"Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis","volume":"54","author":"Leandro","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.xjidi.2026.100508_bib10","article-title":"Efficacy and safety of low dose rituximab in pemphigus: an updated systematic review and meta-analysis","volume":"16","author":"Liu","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.xjidi.2026.100508_bib11","doi-asserted-by":"crossref","DOI":"10.1111\/dth.12763","article-title":"Rituximab therapy in pemphigus: a long-term follow-up","volume":"32","author":"Loi","year":"2019","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.xjidi.2026.100508_bib12","doi-asserted-by":"crossref","first-page":"e789","DOI":"10.1016\/S2665-9913(21)00251-4","article-title":"Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study","volume":"3","author":"Moor","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.xjidi.2026.100508_bib13","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1038\/jid.2008.178","article-title":"B-cell depletion immunotherapy in pemphigus: effects on cellular and humoral immune responses","volume":"128","author":"Mouquet","year":"2008","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.xjidi.2026.100508_bib14","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1182\/blood-2011-09-380949","article-title":"The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL","volume":"119","author":"M\u00fcller","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.xjidi.2026.100508_bib15","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.jaad.2008.01.012","article-title":"Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus","volume":"58","author":"Murrell","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2026.100508_bib16","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jaad.2018.02.021","article-title":"Diagnosis and management of pemphigus: recommendations of an international panel of experts","volume":"82","author":"Murrell","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2026.100508_bib17","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1056\/NEJMoa0904452","article-title":"Rituximab, B-lymphocyte depletion, and preservation of beta-cell function","volume":"361","author":"Pescovitz","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.xjidi.2026.100508_bib18","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1093\/rheumatology\/key428","article-title":"Effect of rituximab treatment on T and B cell subsets in lymph node biopsies of patients with rheumatoid arthritis","volume":"58","author":"Ramwadhdoebe","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.xjidi.2026.100508_bib19","doi-asserted-by":"crossref","DOI":"10.1186\/ar2789","article-title":"Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis","volume":"11","author":"Rehnberg","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.xjidi.2026.100508_bib20","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1111\/bcp.13271","article-title":"Population pharmacokinetics of rituximab in patients with diffuse large B-cell lymphoma and association with clinical outcome","volume":"83","author":"Rozman","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.xjidi.2026.100508_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1138765","article-title":"Optimal time for COVID-19 vaccination in rituximab-treated dermatologic patients","volume":"14","author":"Seree-Aphinan","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.xjidi.2026.100508_bib22","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1111\/ced.15213","article-title":"Comparison of the efficacy and cost-effectiveness of an immunologically targeted low-dose rituximab protocol with the conventional rheumatoid arthritis protocol in severe pemphigus","volume":"47","author":"Singh","year":"2022","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.xjidi.2026.100508_bib23","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1136\/ard.2007.080960","article-title":"Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response","volume":"67","author":"Thurlings","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.xjidi.2026.100508_bib24","doi-asserted-by":"crossref","first-page":"644","DOI":"10.3899\/jrheum.211152","article-title":"Time since rituximab treatment is essential for developing a humoral response to COVID-19 mRNA vaccines in patients with rheumatic diseases","volume":"49","author":"Troldborg","year":"2022","journal-title":"J Rheumatol"},{"key":"10.1016\/j.xjidi.2026.100508_bib25","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/j.ard.2025.06.2120","article-title":"Effects of different B-cell-depleting strategies on the lymphatic tissue","volume":"84","author":"Tur","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.xjidi.2026.100508_bib26","doi-asserted-by":"crossref","first-page":"928","DOI":"10.2340\/00015555-2116","article-title":"Efficacy of rituximab for pemphigus: a systematic review and meta-analysis of different regimens","volume":"95","author":"Wang","year":"2015","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.xjidi.2026.100508_bib27","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa2028564","article-title":"Rituximab versus mycophenolate mofetil in Patients with pemphigus vulgaris","volume":"384","author":"Werth","year":"2021","journal-title":"N Engl J Med"}],"container-title":["JID Innovations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667026726000615?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667026726000615?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T16:43:24Z","timestamp":1792169004000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667026726000615"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2667026726000615"],"URL":"https:\/\/doi.org\/10.1016\/j.xjidi.2026.100508","relation":{},"ISSN":["2667-0267"],"issn-type":[{"value":"2667-0267","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Complete remission after rituximab therapy of pemphigus: Real-world evidence on dosing regimens and retreatment strategies","name":"articletitle","label":"Article Title"},{"value":"JID Innovations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xjidi.2026.100508","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}],"article-number":"100508"}}